Sumitomo Heavy Industries
6302.TMEDIUMScore: 32.5Nuclear Medicine / Fusion · Weight: 4%· Data as of 2026-05-14
Investment Thesis
World's largest cryocooler manufacturer — irreplaceable in ITER fusion (confirmed procurement), MRI superconducting magnets, semiconductor ion implanters, and emerging quantum computing pre-coolers. Q1 FY2026 Mechatronics OP +40% YoY with SHI explicitly citing semiconductor cryocooler demand recovery in US and China. NeuCure BNCT cancer treatment: 3 Japan clinical sites + first overseas install (China Hainan, FY2025 target); Dec 2024 orphan device designation for glioma/meningioma dramatically expands TAM. Trading at PBR ~0.96x (below book) with a strong ¥1,158B (+24% YoY) order backlog providing multi-year revenue visibility. New demand vectors: liquid hydrogen zero-boil-off (hydrogen society) and quantum computing pre-coolers (5,000+ units/yr needed by 2027).
Risk
Logistics & Construction segment (cranes, excavators) OP -45% FY2025 and -40% Q1 FY2026 due to US tariff impact and heavy equipment cycle normalization — drags blended margins. FCF turned negative in FY2025 (-¥2.3B vs prior +¥11B); capex elevated during mid-term plan investment phase. Mid-term OP target ¥80B for FY2026 now looks out of reach (only ¥60B guided — 25% below target). ROE ~5% below cost of equity; ROIC ~3.5% vs 7% target. ITER first plasma delayed to 2035.
Monitoring Trigger
BNCT: if additional Japan hospital contract announced, add 1-2%. Cryocooler: if Q2 FY2026 Mechatronics OP sustains >+20% YoY growth, upgrade to MEDIUM-HIGH. L&C: if US tariff costs not abating by Q2 FY2026 (Aug results), flag as structural drag. FCF: if FY2026 full-year FCF remains negative, reduce position weight.
Key Dates
Key Metrics
Business Segments
| Segment | Revenue | Share | Description |
|---|---|---|---|
| Mechatronics | ¥200B | 19% | Cryocoolers (ITER, MRI), injection molding machines |
| Industrial Machinery | ¥350B | 33% | Cyclotrons, accelerators, forging presses |
| Logistics & Construction | ¥280B | 26% | Cranes, excavators |
| Energy & Lifelines | ¥240B | 22% | Power turbines, water treatment |
Supply Chain Evidence
| Evidence | Customer | Product | Detail |
|---|---|---|---|
| confirmed | ITER Organization | Cryocoolers for fusion reactor cryogenic system | ITER assembly ongoing (vacuum vessel + central solenoid integration, Apr 2026). First plasma now 2035. SHI is specified cryocooler supplier. Ongoing procurement. |
| confirmed | KEK (J-PARC) and JAXA | Cryocoolers for particle accelerators and satellites | SuperKEKB and J-PARC facilities. JAXA satellite applications (~60 years heritage). |
| confirmed | Semiconductor manufacturers (US and China) | Cryocoolers for ion implanters and cryo-pumps | Q1 FY2026 Mechatronics OP +40% YoY; SHI cited semiconductor cryocooler demand recovery in US and China as key driver. |
| confirmed | Hospitals (NeuCure BNCT) | BNCT accelerator-based cancer treatment system | 3 clinical sites in Japan. First overseas: Hainan Boao Lecheng, China (planned FY2025 operations). Orphan device designation Dec 2024 for glioma/meningioma. |
| probable | GE HealthCare / Siemens Healthineers (MRI) | GM-type cryocoolers for MRI superconducting magnets | SHI is world #1 in GM cryocoolers; GE/Siemens are dominant MRI OEMs. Stable recurring demand. |